These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36729996)

  • 1. Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being.
    Moreton SG; Arena AFA; Foy Y; Menzies RE
    Death Stud; 2023; 47(10):1115-1126. PubMed ID: 36729996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
    Sweat NW; Bates LW; Hendricks PS
    J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.
    Davis AK; Barrett FS; Griffiths RR
    J Contextual Behav Sci; 2020 Jan; 15():39-45. PubMed ID: 32864325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.
    Nikolaidis A; Lancelotta R; Gukasyan N; Griffiths RR; Barrett FS; Davis AK
    J Affect Disord; 2023 Mar; 324():239-249. PubMed ID: 36584715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
    Kangaslampi S; Hausen A; Rauteenmaa T
    J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts.
    Graziosi M; Singh M; Nayak SM; Yaden DB
    J Psychoactive Drugs; 2023; 55(5):558-569. PubMed ID: 37679890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-lasting subjective effects of LSD in normal subjects.
    Schmid Y; Liechti ME
    Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience.
    Neitzke-Spruill L; Glasser C
    J Psychoactive Drugs; 2018; 50(4):314-321. PubMed ID: 30052496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing.
    Qiu TT; Minda JP
    J Psychoactive Drugs; 2023; 55(2):123-133. PubMed ID: 35438609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
    Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
    PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.